Effect of Inducers, Incubation Time and Heme Concentration on IC50 Value Variation in Anti-heme Crystallization Assay by Nhien, Nguyen Thanh Thuy et al.
119
Tropical Medicine and Health Vol. 39 No. 4, 2011, pp. 119-126
doi:10.2149/tmh.2011-29
Copyright 2011 by The Japanese Society of Tropical Medicine
Original article
TMH Effect of Inducers, Incubation Time and Heme Concentration on IC50 Value 
Variation in Anti-heme Crystallization Assay
Nguyen Thanh Thuy Nhien
1, Nguyen Tien Huy
3, Dinh Thanh Uyen
1,2, Eric Deharo
4,5, Pham Thi Le Hoa
6,7, 
Kenji Hirayama
3, Shigeharu Harada
1 and Kaeko Kamei
1*
00 Received 15 Septemter, 2011  Accepted 24 October, 2011  Published online 21 December, 2011
© 2011 Japanese Society of Tropical Medicine Abstract: Heme detoxification through crystallization into hemozoin has been suggested as a good target for the
development of screening assays for new antimalarials. However, comparisons among the data obtained from dif-
ferent experiments are difficult, and the IC50 values (the concentrations of drug that are required to inhibit 50% of
hemozoin formation) for the same drug vary widely. We studied the effects of changes in heme concentration (pre-
cursor of β-hematin), incubation time and three inducers (SDS, Tween 20 and linoleic acid) on the IC50 of some
antimalarials (chloroquine, quinine, amodiaquine, and clotrimazole). The results showed that increasing both
inducer concentration and incubation time raised the IC50 of selected antimalarials. Any change in those factors
caused the IC50 value to vary. Standardization of assay conditions is, therefore, necessary to increase reproducibil-
ity and reduce discrepancies in assay performance. Considering all of the variables, the best choice of inducers is
in the order of SDS > Tween 20 > linoleic acid.
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INTRODUCTION
Malaria, which is caused by Plasmodium parasites, is
one of the most common parasitic diseases in tropical coun-
tries. Fast-spreading resistance to current antimalarial drugs
and the absence of a commercialized vaccine make malaria
a global public health priority [1]. The development of a
screening method is thus important in the search for new
drugs against malaria.
During its intraerythrocytic cycle, the malaria parasite
degrades hemoglobin in erythrocytes in order to feed and
releases free heme which is very toxic to both the host cells
and the malarial parasite [2–4]. In the absence of heme ox-
ygenase, Plasmodium cannot cleave heme into an open-
chain tetrapyrrole, which is required for cellular excretion
[5]. Thus, to protect itself, Plasmodium detoxifies free heme
following three pathways: neutralization with histidine-rich
protein 2 [6, 7], degradation with reduced glutathione
[8–10], or crystallization into hemozoin (HZ)—a water-
insoluble malarial heme crystal produced in the food vacu-
ole [7, 11]. The last of the three is widely accepted as the
main pathway of heme detoxification in the parasite [12,
13]. A new protein that is extremely potent in converting
heme into HZ was also recently identified [14].
Several antimalarial drugs have been reported to in-
hibit HZ formation. Quinoline, such as chloroquine, amodi-
aquine, quinine, and its derivatives act by decreasing the
rate of HZ formation rather than by blocking its formation
[15]. Some antifungals (ketoconazole and miconazole) have
also been shown to inhibit heme crystallization or to neu-
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tralize heme by reducing glutathione and histidine-rich
protein 2 [9, 10]. HZ is structurally and chemically identical
to β-hematin (BH), an in vitro synthesized heme crystal
[16–18], and it has been suggested that blocking of BH for-
mation is an ideal target for antimalarial screening [13, 19–
22]. Certain factors, such as temperature [23], histidine-rich
protein [6, 7], lipids [24, 25], preformed BH [13], alcohols
[26], and sodium dodecyl sulfate (SDS) [27] have been
deemed to be responsible for promoting BH formation. The
surfactant Tween 20 has also been used as an inducer for
BH formation assays in vitro and for antimalarial candidate
screening [28]. Linoleic acid, a commercially available
fatty acid, has also been implicated in the initiation of BH
formation in vitro [29, 30].
Several methods using different catalytic factors have
been proposed for the measurement of BH crystallization in
the screening of antimalarials [25, 28, 31–33]. However,
comparisons among the data obtained from different exper-
iments are difficult, because the methods for performing
these assays are not standardized. The IC50 values (concen-
trations required to inhibit 50% of BH formation) of the
same drug varied widely, probably due to the use of differ-
ent catalysts or incubation times [15]. Here, the authors sys-
tematically evaluate the effects of substrate heme concen-
tration, incubation time, and the concentration of different
inducers on variation in the IC50 values of several antimalar-
ials in the BH formation inhibition assay.
MATERIALS AND METHODS
Materials
Hemin chloride (heme), chloroquine (diphosphate salt,
CQ), quinine sulfate (Q), primaquine (PQ) and clotrimazole
(CLT) were obtained from Sigma (Japan). Dimethyl sulfox-
ide (DMSO) was purchased from Wako Pure Chemicals
(Osaka, Japan), amodiaquine dihydrochloride [21] from MP
Biomedical Inc (France), and linoleic acid (LA) from
Sigma. All chemicals were of the highest commercially
available grade.
Preparation of heme stock solution
A stock solution of heme was prepared by dissolving
hemin chloride (16.3 mg) in 1 ml of DMSO and then re-
moving the insoluble heme by centrifugation at 7,000 × g
for 10 min. Heme concentration was estimated from the ab-
sorbance at 400 nm after dilution with 100 mM NaOH-
2.5% SDS solution and calculated with a molar extinction
coefficient of 10
5 at 400 nm as described previously [34].
The stock reagent was stored in the dark at 4°C until use.
Preparation of antimalarial drugs and inducers
CQ, AQ and PQ, CLT, and Q were dissolved in dis-
tilled water, DMSO, and 20 mM H2SO4. The concentration
of all drug stock solutions was 20 mM. Drugs were diluted
twofold in series with distilled water to various concentra-
tions from 0 to 1 mM. SDS and Tween 20 were dissolved in
distilled water. LA was dissolved in chloroform, sprayed
and dried on the wall of a microtube with nitrogen gas to
make a thin layer, then suspended in 100 mM acetate buffer
pH 5.2.
Assay of BH formation initiated by Tween 20, SDS and
LA
The synthesis of BH was performed as previously
described [33]. Various concentrations diluted in serial 1:2
in distilled water with Tween 20, SDS or LA were used. The
inducer (Tween 20, SDS or LA) was incubated with 100 μM
of heme in 1 ml of 100 mM acetate buffer pH 5.2 at 37°C for
5 and 12 h. The pH of the buffer used in the assay was sim-
ilar to that of the food vacuole of the malarial parasite where
hemozoin formation takes place [35].
After incubation, the sample was centrifuged at
7,000 × g for 10 min. The pellet was then suspended in 1 ml
of 2.5% SDS buffered with 0.1 M sodium bicarbonate (pH
9.1) and briefly sonicated. After shaking at room tempera-
ture for 1 h to dissolve unreacted heme, the remaining insol-
uble material was recovered by centrifugation. This step
was repeated one more time without sonication, thus pro-
ducing purified BH. In order to determine the amount of
heme crystallized into BH, the purified BH was decrystal-
lized into monomer heme and completely dissolved in 0.1
M NaOH-2.5% SDS for 10 min at room temperature. The
heme concentration in the solution was then calculated as
described above [34].
Inhibition assay of BH formation by antimalarial drugs
Tween 20, SDS or LA was incubated with heme (100
μM) in 1 ml of 100 mM acetate buffer at pH 5.2 in the pres-
ence of various drug concentrations of CQ, AQ, Q, PQ or
CLT. After incubating at 37°C, BH was purified and its con-
centration was calculated as described above. Values ob-
tained from triplicate assays were plotted and IC50 values
were determined by calculating graphically.
Assay of BH formation with various concentration of
substrate heme
Heme ranging from 6.25 to 200 μM was incubated
at 37°C for 5 h with 0.0025% Tween 20, 1% SDS or
0.25 mg/ml LA. The resulting BH was then purified and its
concentration was determined as described above.121 N.T.T. Nhien et al.
Statistical analysis
Data analysis was performed using SPSS 16.0 soft-
ware. Data are expressed as the mean with standard error of
mean (SEM) unless otherwise stated. IC50 values obtained
from three independent experiments in triplicate of each
assay were used in the statistical analysis. Data were
logarithm transformed to ensure normal distribution before
analysis. A student’s t-test for independent samples was
performed and values were considered significant when p <
0.05. Significant differences in IC50 values were analyzed
when the inducers’ concentration, incubation time or sub-
strate concentration varied.
RESULTS
Promotion of BH formation by different inducers
(Figure 1)
The three inducers used in the present study (Tween
20, SDS, and LA) are commercially available and easy to
prepare in order to promote BH formation. After 5 or 12 h
of incubation, the yield of BH formation was maximal with
0.0025% of Tween 20 (Figure 1A), 2% of SDS (Figure 1B)
and 0.25 mg/ml of LA (Figure 1C). The crystal growth
curves showed a sigmoidal pattern similar to that of a previ-
ous report [28]. A further increase in LA concentration low-
ered BH formation, probably because hemin tends to accu-
mulate at the surface of the assay mixture [29]. SDS con-
verted heme into BH more efficiently (maximal BH fraction
around 50%, Figure 1B) than Tween 20 or LA (40% and
30%, Figure 1A and C respectively) as previously described
[28–30].
Effect of inducer concentration on IC50 values of antima-
larials
To examine the effect of inducer concentration on IC50,
the inhibitory effects of antimalarial drugs (CQ, AQ, Q, PQ)
and one antifungal (CLT) were studied using two different
concentrations of each inducer. Those concentrations were
chosen from the result obtained in Figure 1, when BH for-
mation reached around 50% or maximal yield. Tween 20
was used at 0.025% and 0.00125%, SDS at 1% and 0.5%,
and LA at 0.25 mg/ml and 1 mg/ml.
Various concentrations of drugs were incubated with
100 μM heme for 5 and 12 h. Three independent experi-
ments in triplicate showed that the antimalarials (CQ, AQ,
Q) and CLT were able to inhibit BH formation whatever the
inducer used (Table 1, 2 and 3), while PQ had no inhibiting
effect on BH formation (IC50 value > 2000 μM in any of the
assays, data not shown). It has been reported that PQ has
no potency to inhibit heme crystallization and no anti-
plasmodium activity toward intraerythrocytic parasites
[36]. IC50 values were also used to analyze statistical differ-
ences in the changes and were considered significant when
p < 0.05. Increasing the concentration of inducer led to in-
creased IC50 values. Increasing the concentration of Tween
20 significantly increased IC50 values for all tested drugs,
from 1.8 to 2.7 times after 5 h (p < 0.001) and 1.2 to 3.6
times (p < 0.01) after 12 h of incubation, even though heme
concentration was constant (Table 1). With LA, the IC50
also increased from 1.4 to 2.3 times after 5 h (p < 0.05) and
1.9 to 2.8 times (p < 0.001) after 12 h of incubation
(Table 3). These findings indicate that the interaction of
Fig. 1.  Follow-up of BH formation with increased concentra-
tions of Tween 20 (A), SDS (B) and linoleic acid (C)
after 12 h (open diamond) and 5 h (open square) of in-
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heme and/or drug and inducers (Tween and LA) affected the
anti-heme crystallization activities of the drugs. In contrast,
the IC50 values of the drugs increased only slightly with
SDS, i.e. 1.03 to 1.5 times after both 5 (p = 0.055) and 12 h
of incubation (p = 0.11) which was not significant (Table 2).
This statistical analysis suggested that SDS is a better in-
ducer, with less variation in IC50 values, in inhibiting BH
formation assays compared with other tested inducers.
The CQ index value, which is the ratio between the
IC50 value of a tested drug and the IC50 value of CQ under
the same reaction conditions [37], was also calculated. This
index showed the activity of the tested drug compared with
CQ. CQ index values were affected by different inducers
used in the assay, a finding that was closely consistent with
another study [32]. This might indicate that different induc-
ers interact with heme and/or the drug in different modes.
CQ index values of Q and CLT in almost all the assays were
higher than 1 showing that Q and CLT have a weaker bind-
ing coefficient to heme than CQ. In contrast, the CQ index
of AQ was lower than 1, suggesting stronger binding, which
was consistent with previous reports [32, 37].
Effect of incubation time on IC50 value
It has been reported that incubation duration also af-
fects the IC50 value [15]. The effects of two different incu-
bation times, 5 h and 12 h, on the IC50 values of four antima-
larial drugs, CQ, AQ, Q, and CLT, were examined further.
These two incubation times were selected because the yield
of BH reached the maximum after 12 h incubation, while at
5 h, the BH fraction reached more than half of the maximum
with each inducer. A direct correlation was also found be-
tween IC50 values and incubation times (Tables 1–3). These
values of all the tested drugs increased when incubation
time was prolonged in all assays with different inducers, a
finding consistent with a previous report [15]. When the in-
cubation duration was lengthened from 5 h to 12 h, IC50 val-
ues were increased in all tested drugs, between 1.4 and 2.5
times (p < 0.001) and 1.3 and 1.9 times (p < 0.05) when us-
ing Tween 20 as an inducer at 0.00125% or 0.0025% of con-
centration (Table 1); 1.1 and 2.6 times (p < 0.01) and 1.1
and 1.9 (p < 0.01) with SDS as an inducer at 0.5% or 1% of
concentration (Table 2); and 1.2 and 1.5 times (p = 0.11)
and 1.1 and 2.2 times (p < 0.05) with LA as an inducer at
0.25 mg/ml or 1 mg/ml concentration (Table 3). In addition,
the statistical analysis showed significant differences be-
tween IC50s when incubation time varied (p < 0.05), except
when using 0.25 mg/ml LA as an inducer. These results also
suggested that antimalarial drugs do not completely block
BH formation but simply slow the rate [15].
Table 1. IC50s (µM) of drugs on BH formation induced by
Tween 20.
SD, standard deviation; CQ index, IC50 of drug/ IC50 of CQ
Mean values from three experiments in triplicate
Drugs
Tween 20 concentration
Incubation 
time
0.0025% 0.00125%
IC50 SD CQ 
index IC50 SD CQ 
index
CQ 59.0 6.8 1.0 48.5 2.4 1.0
12 h
AQ 45.3 1.2 0.8 25.0 1.7 0.5
Q 170.0 12.3 2.9 46.8 3.5 1.0
CLT 105.0 11.6 1.8 75.7 6.1 1.6
CQ 44.5 5.7 1.0 25.0 2.2 1.0
5 h
AQ 25.3 2.1 0.6 12.8 0.5 0.5
Q 90.0 9.1 2.0 33.0 1.2 1.3
CLT 82.3 17.0 1.9 30.3 2.5 1.2
Table 2. IC50s (µM) of drugs on BH formation induced by
SDS.
SD, standard deviation; CQ index: IC50 of drug/ IC50 of CQ
Mean values from three experiments in triplicate
Drugs
SDS concentration
Incubation 
time
1% 0.5%
IC50 SD CQ 
index IC50 SD CQ 
index
CQ 376.0 25.2 1.0 245.0 12.3 1.0
12 h
AQ 412.0 17.7 1.1 380.0 17.3 1.6
Q 201.0 11.1 0.5 180.0 13.2 0.7
CLT 215.3 10.1 0.6 195.7 7.1 0.8
CQ 196.7 20.6 1.0 185.3 18.0 1.0
5 h
AQ 223.3 15.8 1.1 146.7 23.1 0.8
Q 151.7 9.2 0.7 102.7 9.5 0.6
CLT 192.5 13.5 1.0 187.5 10.6 1.0
Table 3. IC50s (µM) of drugs on BH formation induced by
linoleic acid.
SD, standard deviation; CQ index: IC50 of drug/IC50 of CQ
Mean values from three experiments in triplicate
Drugs
Linoleic acid concentration
Incubation 
time
1mg/ml 0.25mg/ml
IC50 SD CQ 
index IC50 SD CQ 
index
CQ 90.9 8.2 1.0 32.5 6.4 1.0
12 h
AQ 103.3 12.3 1.1 41.0 7.2 1.3
Q 62.5 2.9 0.7 27.5 4.0 0.9
CLT 203.3 13.5 2.2 108.3 13.5 3.3
CQ 51.0 8.5 1.0 28.7 2.9 1.0
5 h
AQ 46.7 1.2 0.9 27.5 4.1 1.0
Q 33.3 5.8 0.7 23.0 2.0 0.8
CLT 185.0 17.1 3.6 80.5 5.3 2.8123 N.T.T. Nhien et al.
Effect of heme concentration on IC50 value
To examine the effect of heme concentration on IC50
values, preliminary experiments were performed to explore
the yield of BH using various concentrations of substrate
heme. BH formation was induced with 0.0025% of Tween
20, 1% of SDS, or 0.25 mg/ml of LA. It was found that with
concentrations of heme ranging from 50 μM up to 200 μM,
the BH formation increased, whatever the inducer used
(Figure 2). However, the yield of BH formation differed
from one inducer to another, with SDS and Tween 20 being
more efficient than LA.
When the heme concentration increased the IC50 val-
ues increased (Table 4). With SDS as an inducer, the IC50
values of the drugs increased from 3 to 6.5 times (p < 0.001)
when heme concentration increased from 50 to 100 μM and
about 6 to 9 times (p < 0.01) when heme concentration in-
creased to 200 μM. It is interesting to note that when heme
concentration varied from 50 to 100 μM or 100 to 200 μM,
the variation in IC50 values was less significant with Tween
20 and LA (p = 0.18; 0.001 and 0.94; 0.16, respectively)
than with SDS, even though more drugs were needed to
bind heme substrate or active sites of crystallization. A clear
positive correlation between IC50 and heme concentration
was observed when using SDS as inducer. Moreover, a
lower heme concentration used in the assay reduced the
variation in IC50 values.
DISCUSSION
Heme detoxification through crystallization into HZ
has been suggested as an ideal target for the development of
antimalarial screening methods [13, 19–22]. Recently, new
high throughput screening assays have been developed [28,
38]. However, comparisons among the data obtained from
different experiments are difficult, and the IC50 values for
the same drug varied widely, probably due to the use of dif-
ferent catalysts or incubation times [15]. The present study
evaluated the effects of heme concentration, incubation
time, and different concentration of inducers on variations
in the IC50 value of selected antimalarials to show the im-
portance of standardization of screening methods.
In another study, parasite extracts were used to pro-
mote BH formation [32]. This required tedious preparations
and parasite culture. In contrast, we used three inducers
Fig. 2.  Follow-up of BH formation with increasing concentra-
tions of heme promoted with 0.0025% Tween 20 (open
square), 1% SDS (open circle), and 0.25 mg/ml linoleic
acid (open triangle) after 5h of incubation
Table 4. IC50s (µM) of drugs on BH formation induced by Tween 20, SDS or linoleic acid after 5 h of
incubation at increasing concentrations of heme
SD, standard deviation; CQ index: IC50 of a drugs/IC50 of CQ
Mean values from three experiments in triplicate
Drugs
Heme concentration
Inducer 50 µM1 0 0   µM2 0 0   µM
IC50 SD CQ 
index IC50 SD CQ 
index IC50 SD CQ 
index
CQ 40.0 8.7 1.0 44.5 1.7 1.0 95.0 8.4 1.0
Tween 20 
0.0025%
AQ 24.5 2.7 0.6 25.3 2.1 0.6 55.0 2.1 0.6
Q 80.5 1.6 2.0 90.0 9.1 2.0 198.5 12.7 2.1
CLT 41.3 3.5 1.0 82.3 17.0 1.9 240.3 19.1 2.5
CQ 48.0 7.1 1.0 196.7 20.6 1.0 361.7 22.6 1.0
SDS 1%
AQ 34.5 12.1 0.7 223.3 5.8 1.1 290.0 78.1 0.8
Q 32.5 10.6 0.7 151.7 9.2 0.7 193.3 24.7 0.5
CLT 60.2 5.0 1.3 192.5 3.5 1.0 353.3 30.6 1.0
CQ 26.0 2.7 1.0 28.7 2.9 1.0 31.0 6.7 1.0
Linoleic acid 
0.25 mg/ml
AQ 13.5 0.6 0.5 14.3 2.1 0.5 23.0 1.8 0.7
Q 24.3 2.6 0.9 23.0 2.0 0.8 48.4 1.3 1.6
CLT 81.3 1.4 3.1 80.5 3.5 2.8 116.3 1.0 3.8124 Tropical Medicine and Health Vol.39 No.4, 2011
(Tween 20, SDS, and LA) that are commercially available
and easy to prepare. All have been shown to promote BH
formation (Figure 1), which is consistent with previous re-
ports [27–30]. IC50 values of all drugs in the inhibition assay
were calculated and the variation was measured when incu-
bation time, inducer or heme concentration changed. The
results showed a direct correlation between IC50 values,
concentration of inducers and incubation duration (Table 1–
3) with any of the inducers used. IC50 values of all drugs in
the assays using SDS were much higher than those obtained
from the assays using other inducers (Table 1–4). This may
be due to the ability of SDS to help dissolve monomeric
heme in an acid medium [27].
Among the inducers studied, SDS showed the highest
impact on IC50 variation, while less significant increases
were observed with Tween 20 and LA when heme concen-
tration of the assay changed (Table 4). These discrepancies
might be due to the different states of inducers. The concen-
trations of Tween 20 used in this study were slightly lower
than its critical micelle concentration (cmc), so it was in
monomer or small aggregated form. LA at pH 5.2 may also
disperse in monomer or small aggregated form. Therefore,
the interaction of heme and/or the drugs with these small
forms of inducers might affect the inhibition of heme crys-
tallization by antimalarials. In particular, the interaction of
LA and drugs might disturb the heme crystallization by
blocking the interaction of heme and LA, as indicated by the
less significant increase in IC50 regardless of the increase in
heme concentration. In contrast, SDS concentration was
higher than its cmc, and thus a dynamic equilibrium existed
between micelle and monomer. Therefore, heme and drug
might be intercalated to the hydrophobic binding site of the
SDS micelle, and might bind to inhibit heme crystallization.
Further studies are required to elucidate the mechanism of
this discrepancy.
Increasing the IC50 values is likely to lead to false neg-
ativity of tested drugs and could necessitate more testing.
Thus, the results suggest that a lower concentration of heme
is better for assay performance with low variation in IC50
values. In addition, a short incubation time promises to save
time and also lower the IC50 variation.
Our results showed that the ability of the inducers to
achieve the narrowest variation in IC50 value was in the or-
der of SDS > LA > Tween 20, when the concentration of in-
ducers and the incubation time increased. Positive correla-
tions between heme concentration and IC50 were clearly
seen with SDS as an inducer. In contrast, a larger variation
in IC50 value was seen with SDS than with LA or Tween 20,
indicating that more of the drug is required when SDS is
used for screening of antimalarial compounds. The ability
of inducers to achieve the narrowest variation in IC50 values
was on the order of LA > Tween 20 > SDS when concentra-
tion of heme changed. Considering the stability and easy
preparation of SDS and Tween 20 stock solution compared
to LA, as well as the advantages of high throughput assay
for antimalarial screening, the choice of inducers should be
on the order of SDS > Tween 20 > LA.
CONCLUSION
Any change in incubation time, inducer or heme con-
centration affected the variation in IC50 values. Increases in
both the inducer concentration and incubation time raised
the IC50 of some antimalarials used in this study. Therefore,
standardization of assay conditions is necessary to increase
reproducibility and avoid false negativity in the perfor-
mance of assays for antimalarial screening based on the in-
hibition of heme crystallization.
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